Cancer Immunotherapy Offers Hope for Long-Term HIV Control

16 October 2025
New Phase 1 clinical trial, reports that budigalimab, an immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), was safe, well tolerated, and showed early signs of helping the immune system control HIV without daily medication… Read More…